Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health: Healthy Gift
Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.
Hims & Hers: Great Value Amid Unwarranted Concerns (Rating Upgrade)
Hims & Hers stock has dropped ~30% from recent peaks despite raising its outlook for FY24. Investors are concerned over projections for the company's weight loss compound drugs, especially if the FDA-approved Wegovy and Ozempic see better supply. Still, the company's weight loss revenue is only contributing a small fraction of its outstanding growth rates today, built across a wide range of specialties.
Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Subscriber growth reaccelerated, focus on personalized products, over 40% subscribers use personalized solutions. Stock-based compensation concern, $100M buyback program, increased marketing spend, positive outlook for Hims' future. GLP-1 offering still in a gray area, path forward looks difficult but possible.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Hims & Hers Health the Best Growth Stock for You?
Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.
Hims & Hers Health Boosts Outlook. Is This a Golden Opportunity to Buy the Stock?
Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Stock Crashed but This Is a Growth Machine
Don't overlook the 52% growth in the second quarter.
Hims & Hers Health, Inc. (HIMS) Q2 2024 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder & CEO Yemi Okupe - CFO Conference Call Participants Maria Ripps - Canaccord Allen Lutz - Bank of America Jack Wallace - Guggenheim Securities Daniel Grosslight - Citi Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Glen Santangelo - Jefferies George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Hims & Hers Second Quarter 2024 Earnings Conference Call.
Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.
Shares of Hims & Hers, known for hair-loss treatments and Viagra, rally amid market panic
Shoppers might be spending less or seeking cheaper deals on takeout food and household items, and investors on Monday were panicking about the U.S. economy. But Hims & Hers Health Inc. — the online telehealth platform best known for selling hair-loss treatments, Viagra and Cialis — said customers are still piling in.
